PMID- 18396691
OWN - NLM
STAT- MEDLINE
DCOM- 20100304
LR  - 20151119
IS  - 0253-3766 (Print)
IS  - 0253-3766 (Linking)
VI  - 29
IP  - 10
DP  - 2007 Oct
TI  - [Weekly paclitaxel and carboplatin with concurrent three dimensional conformal 
      radiotherapy for locally advanced non small cell lung cancer].
PG  - 769-72
AB  - OBJECTIVE: To evaluate the toxicity and efficacy of weekly chemotherapy of 
      paclitaxel and carboplatin with concurrent three dimensional conformal 
      radiotherapy (3D-CRT)for locally advanced non small cell lung cancer(NSCLC). 
      METHODS: From July 2002 to July 2004, a non-randomized prospective study of 52 
      patients with locally advanced NSCLC treated with 3D-CRT and chemotherapy by 
      paclitaxel and carboplatin were carried out. Of the 52 patients, 21 received 
      concurrent chemoradiation with 3D-CRT and weekly paclitaxel and carboplatin 
      (concurrent chemoradiation group), 31 received sequential chemoradiation with 
      paclitaxel and carboplatin and 3D-CRT (sequential chemoradiation group). In the 
      concurrent chemoradiation group, paclitaxel 40 mg/m2 was administered 
      intravenously for 1 hour. Carboplatin of 1.5 AUC/cycle was used after 
      administration of paclitaxel on D1, D8, D15, D29, D36 and D143. In the sequential 
      chemoradiation group, two cycles of chemotherapy were given at two weeks before 
      radiotherapy. Paclitaxel 150 mg/m2 and carboplatin 5 AUC/cycle were administered 
      on D1 and D21. 3D-CRT was given at two weeks after the second cycle of 
      chemotherapy provided that the hematological examination was normal. 3D-CRT was 
      given at 1.8-2.0 Gy/f to a total dose of 60-66 Gy/6-8 weeks. RESULTS: All the 
      patients completed the trial, but 12 had prolongation of treatment time for more 
      than 1 week due to severe leucopenia with 5 in concurrent chemoradiation group 
      and 7 in sequential chemoradiation group. The rate of complete response (CR), 
      partial response (PR), progress of disease (NC + PD) and overall response was 
      9.5% (2/21), 71.4% (15/21), 19.0% (4/21) and 81.0%, respectively, in concurrent 
      group, versus 6.5% (2/31), 67.7% (21/31), 25.8% (8/31) and 74.2% in sequential 
      group (CR), respectively. II-III grade of esophagitis, pneumonia and 
      leukocytopenia observed in concurrent chemoradiation group was 61.9% (13/21), 
      41.9% (13/31) and 23.8% (5/21) ,versus 22.6% (7/31), 42.9 % (9/21) and 19.4% 
      (6/31), respectively, in the sequential chemoradiation group. One of those 
      patients in concurrent chemoradiation group had IV grade of leukocytopenia. The 
      overall median survival time was 17.5 months with 19.0 months for concurrent 
      chemoradiation group, 15.8 months for sequential chemoradiation group. The 
      Overall 1-, 2-year survival rate was 72.0%, 37.0%, respectively and 1 - and 2 - 
      year local control rate was 75.0% and 75.0%. CONCLUSION: Our data indicate that 
      concurrent chemoradiotherapy is safe and effective for locally advanced non small 
      cell lung cancer. Concurrent chemoradiotherapy may be helpful in improving 
      response and survival than sequential one, but no significant difference is 
      observed between two groups in this series(P > 0.05). Further randomized 
      prospective study is still needed to prove it.
FAU - Wang, Jun
AU  - Wang J
AD  - Department of Radiation Oncology, Tianjin Cancer Hospital, Tianjin Medical 
      University, Tianjin 300060, China.
FAU - Pang, Qing-Song
AU  - Pang QS
FAU - Wang, Ping
AU  - Wang P
FAU - Wang, Jing
AU  - Wang J
FAU - Wang, Wei
AU  - Wang W
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhonghua Zhong Liu Za Zhi
JT  - Zhonghua zhong liu za zhi [Chinese journal of oncology]
JID - 7910681
RN  - BG3F62OND5 (Carboplatin)
RN  - P88XT4IS4D (Paclitaxel)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Carboplatin/administration & dosage
MH  - Carcinoma, Non-Small-Cell Lung/*therapy
MH  - Combined Modality Therapy
MH  - Drug Administration Schedule
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Leukopenia/chemically induced/etiology
MH  - Lung Neoplasms/pathology/*therapy
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Paclitaxel/administration & dosage
MH  - Prospective Studies
MH  - *Radiotherapy, Conformal
MH  - Remission Induction
MH  - Survival Rate
EDAT- 2008/04/10 09:00
MHDA- 2010/03/05 06:00
CRDT- 2008/04/10 09:00
PHST- 2008/04/10 09:00 [pubmed]
PHST- 2010/03/05 06:00 [medline]
PHST- 2008/04/10 09:00 [entrez]
PST - ppublish
SO  - Zhonghua Zhong Liu Za Zhi. 2007 Oct;29(10):769-72.